Skip to Main Content

Joachim Baehring, MD

Professor of Neurology and of Neurosurgery; Associate Chief, Neurology; Director, Neuro-Oncology Fellowship Program, Neurology; Vice Chair, Clinical Affairs, Neurology

Contact Information

Joachim Baehring, MD

Mailing Address

  • Neurology

    Neuro-Oncology 15 York Street LLCI 912, PO Box 208028

    New Haven, CT, 06520-8082

    United States

Research Summary

The primary foci of Dr. Baehring's laboratory work are primary brain tumors and neurological complications of cancer.

Dr. Baehring is involved in clinical and translational research at Yale University School of Medicine. He is an investigator on numerous therapeutic trials for patients with glioblastoma, lymphoma, and other brain tumors. Other research interests include the molecular pathogenesis and development of molecular markers for primary CNS lymphoma.

Specialized Terms: Molecular markers of cancer; Nervous system lymphoma

Research Interests

Brain Neoplasms; Lymphoma; Medical Oncology; Neurology; Neurosurgery

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma
Brain and Nervous SystemA Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Brain and Nervous SystemGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Brain and Nervous SystemPhase 1: BGB-290 in combination with TMZ in patients w/ IDH1/2-mutant WHO grade II-IV recurrent glioma: Phase 2: Grade II-III patients in will be stratified into 2 arms based on the timing of prior alkylator chemotherapy exposure; a third arm will include the subset of glioblastoma (grade IV) patients
Brain and Nervous SystemGenomically-Guided Treatment Trial in Brain Metastases
Brain and Nervous SystemPhase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Brain and Nervous SystemPhase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Brain and Nervous SystemPhase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Anus; Bones and Joints; Brain and Nervous System; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Kaposi's sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, skin; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Cervix; Urinary BladderNCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas